Dyslipidemia is a risk factor for cardiovascular diseases（CVDs）in patients with diabetes,and non-high-density lipoprotein cholesterol（non-HDL-C）is a better predictor of CVDs than low-density lipoprotein cholestero...Dyslipidemia is a risk factor for cardiovascular diseases（CVDs）in patients with diabetes,and non-high-density lipoprotein cholesterol（non-HDL-C）is a better predictor of CVDs than low-density lipoprotein cholesterol（LDL-C）in patients with diabetes.Therefore,we aimed to investigate the distribution of non-HDL-C and the prevalence of high non-HDL-C level in Chinese patients with diabetes mellitus and identify the展开更多
Objective To study the relationship between growth hormone (GH) and microangiopathy in patients with diabetes mellitus in order to elucidate pathogenesis on microangiopathy in diabetics. Methods GH and insulin (INS) ...Objective To study the relationship between growth hormone (GH) and microangiopathy in patients with diabetes mellitus in order to elucidate pathogenesis on microangiopathy in diabetics. Methods GH and insulin (INS) were detected by radioimmunoassay, and blood sugar (BS) was detected by oxydase method. Results 138 NIDDM diabetics were examined. The concentration of serum GH in diabetics without microangiopathy (2.3±1.2 μg/L) was higher than in normal people (1.0±1.2 μg/L) and GH in diabetics with microangiopathy (5.74±1.94 μg/L) was higher than in diabetics without microangiopathy. The differences were significant ( P <0.01). As the history of diabetes went on, the level of GH in serum increased, and the incidence of microangiopathy increased too. The correlation of GH in serum with BS was parallel. The correlation of GH in serum with INS was not apparent. 27 IDDM diabetics were examined, their level of GH in serum (6.8±3.4 μg/L) was higher than that of NIDDM diabetics (4.6±1.8 μg/L). They were all patients with microangiopathy. Conclusion The rise of GH in serum may be an important pathogeny that causes microangiopathy in diabetics.展开更多
Background Vorapaxar reduces cardiovascular death, myocardial infarction （MI）, or stroke in patients with previous MI while increasing bleeding. Patients with diabetes mellitus （DM） are at high risk of recurrent t...Background Vorapaxar reduces cardiovascular death, myocardial infarction （MI）, or stroke in patients with previous MI while increasing bleeding. Patients with diabetes mellitus （DM） are at high risk of recurrent thrombotic events despite standard therapy and may derive particular benefit from antithrombotic therapies. The Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 trial was a randomized, double-blind, placebo-controlled trial of vorapaxar in patients with stable atherosclerosis.展开更多
基金funded by the Scientific Research Foundation of the Health Bureau of Jilin Province,China(grant number:2011Z116)the National Natural Science Foundation of China with grant(grant number:81573230)
文摘Dyslipidemia is a risk factor for cardiovascular diseases（CVDs）in patients with diabetes,and non-high-density lipoprotein cholesterol（non-HDL-C）is a better predictor of CVDs than low-density lipoprotein cholesterol（LDL-C）in patients with diabetes.Therefore,we aimed to investigate the distribution of non-HDL-C and the prevalence of high non-HDL-C level in Chinese patients with diabetes mellitus and identify the
文摘Objective To study the relationship between growth hormone (GH) and microangiopathy in patients with diabetes mellitus in order to elucidate pathogenesis on microangiopathy in diabetics. Methods GH and insulin (INS) were detected by radioimmunoassay, and blood sugar (BS) was detected by oxydase method. Results 138 NIDDM diabetics were examined. The concentration of serum GH in diabetics without microangiopathy (2.3±1.2 μg/L) was higher than in normal people (1.0±1.2 μg/L) and GH in diabetics with microangiopathy (5.74±1.94 μg/L) was higher than in diabetics without microangiopathy. The differences were significant ( P <0.01). As the history of diabetes went on, the level of GH in serum increased, and the incidence of microangiopathy increased too. The correlation of GH in serum with BS was parallel. The correlation of GH in serum with INS was not apparent. 27 IDDM diabetics were examined, their level of GH in serum (6.8±3.4 μg/L) was higher than that of NIDDM diabetics (4.6±1.8 μg/L). They were all patients with microangiopathy. Conclusion The rise of GH in serum may be an important pathogeny that causes microangiopathy in diabetics.
文摘Background Vorapaxar reduces cardiovascular death, myocardial infarction （MI）, or stroke in patients with previous MI while increasing bleeding. Patients with diabetes mellitus （DM） are at high risk of recurrent thrombotic events despite standard therapy and may derive particular benefit from antithrombotic therapies. The Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 trial was a randomized, double-blind, placebo-controlled trial of vorapaxar in patients with stable atherosclerosis.
